Literature DB >> 20930505

Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner.

Heekyung Chung1, Joy Chaudhry, Claudia G Lopez, John M Carethers.   

Abstract

Several studies indicate that the DNA mismatch repair (MMR) system may trigger cytotoxicity upon 5-fluorouracil (5-FU) recognition, but signaling pathways regulated by MMR in response to 5-FU are unknown. We hypothesize that recognition of 5-FU in DNA by MMR proteins trigger specific signaling cascades that results in slowing of the cell cycle and cell death. Whole human genome cDNA microarrays were used to examine relative signaling responses induced in MMR-proficient cells after 5-FU (5 μM) treatment for 24 hours. Analysis revealed 43 pathways differentially affected by 5-FU compared to control (P 1.4-fold) and downregulated cdc25C, cyclins B1 and B2, histone H2A, H2B, and H3 (< -1.4-fold) over control. Cell cycle analysis revealed a G1/S arrest by 5-FU that was congruent with increased cyclin E and decreased cdc25C protein expression. Importantly, with knockdown of hMLH1 and hMSH2, we observed that decreased histone H3 expression by 5-FU was dependent on hMLH1. Additionally, 5-FU treatment dramatically decreased levels of several histone H3 modifications. Our data suggest that 5-FU induces a G1/S arrest by regulating cyclin E and cdc25C expression, and MMR recognition of 5-FU in DNA may modulate cyclin E to affect the cell cycle. Furthermore, MMR recognition of 5-FU reduces histone H3 levels that could be related to DNA access by proteins and/or cell death during the G1/S phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20930505      PMCID: PMC3230292          DOI: 10.4161/cbt.10.11.13447

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  47 in total

1.  An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair.

Authors:  A Kat; W G Thilly; W H Fang; M J Longley; G M Li; P Modrich
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

2.  Mutation of a mutL homolog in hereditary colon cancer.

Authors:  N Papadopoulos; N C Nicolaides; Y F Wei; S M Ruben; K C Carter; C A Rosen; W A Haseltine; R D Fleischmann; C M Fraser; M D Adams
Journal:  Science       Date:  1994-03-18       Impact factor: 47.728

3.  Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.

Authors:  M Koi; A Umar; D P Chauhan; S P Cherian; J M Carethers; T A Kunkel; C R Boland
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

4.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

Authors:  R Fishel; M K Lescoe; M R Rao; N G Copeland; N A Jenkins; J Garber; M Kane; R Kolodner
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

5.  Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick; M H Veeder; J A Mailliard
Journal:  Ann Intern Med       Date:  1995-03-01       Impact factor: 25.391

6.  Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.

Authors:  S C Remick; J L Grem; P H Fischer; K D Tutsch; D B Alberti; L M Nieting; M B Tombes; J Bruggink; J K Willson; D L Trump
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

7.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

8.  5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line.

Authors:  Renata Matuo; Fabrício Garmus Sousa; Alexandre E Escargueil; Ivana Grivicich; Daniel Garcia-Santos; José Artur Bogo Chies; Jenifer Saffi; Annette K Larsen; João Antonio Pêgas Henriques
Journal:  J Appl Toxicol       Date:  2009-05       Impact factor: 3.446

9.  Mutations of two PMS homologues in hereditary nonpolyposis colon cancer.

Authors:  N C Nicolaides; N Papadopoulos; B Liu; Y F Wei; K C Carter; S M Ruben; C A Rosen; W A Haseltine; R D Fleischmann; C M Fraser
Journal:  Nature       Date:  1994-09-01       Impact factor: 49.962

10.  Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols.

Authors:  Paula M De Angelis; Katherine L Kravik; Siv H Tunheim; Terje Haug; Wenche H Reichelt
Journal:  Mol Cancer       Date:  2004-04-26       Impact factor: 27.401

View more
  6 in total

1.  DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells.

Authors:  Moriya Iwaizumi; Stephanie Tseng-Rogenski; John M Carethers
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

Review 2.  Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Authors:  John M Carethers; Barbara H Jung
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 3.  Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.

Authors:  John M Carethers; Elena M Stoffel
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

4.  Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.

Authors:  Yasushi Hamaya; Carla Guarinos; Stephanie S Tseng-Rogenski; Moriya Iwaizumi; Ritabrata Das; Rodrigo Jover; Antoni Castells; Xavier Llor; Montserrat Andreu; John M Carethers
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

5.  Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.

Authors:  Satoshi Suzuki; Moriya Iwaizumi; Stephanie Tseng-Rogenski; Yasushi Hamaya; Hiroaki Miyajima; Shigeru Kanaoka; Ken Sugimoto; John M Carethers
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

6.  CpG oligodeoxynucleotides enhance chemosensitivity of 5-fluorouracil in HepG2 human hepatoma cells via downregulation of the antiapoptotic factors survivin and livin.

Authors:  Sheng-Ran Liang; Guang-Rui Hu; Li-Juan Fang; Su-Jing Huang; Jin-Song Li; Ming-Yi Zhao; Min-Jie Meng
Journal:  Cancer Cell Int       Date:  2013-10-26       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.